← All trials
NCT06962904
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2025
- Primary completion
- Jul 15, 2027
- Completion date
- Jul 15, 2027
- First posted
- May 8, 2025
- Last posted
- Aug 11, 2025
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centers for Disease Control and Prevention (CDC)Lead sponsor
- University of CincinnatiCollaborator
- Micron Biomedical, IncCollaborator
- Emory UniversityCollaborator
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.